Education: An introduction to the core data for cefiderocol with reflections for a possible role within UK clinical practice

The video in this section is a copy of a recorded webinar organized by Shionogi to launch cefiderocol to the UK market in September 2020. Dr Andreas Karas presents the key clinical data for this new antibiotic for MDR Gram-negative infections, followed by reflections from Professor Jonathan Edgewort...

Descripción completa

Detalles Bibliográficos
Autores principales: Karas, J Andreas, Edgeworth, Jonathan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Supplement Papers
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8251257/
https://www.ncbi.nlm.nih.gov/pubmed/34223150
http://dx.doi.org/10.1093/jacamr/dlab053
_version_ 1783717088173490176
author Karas, J Andreas
Edgeworth, Jonathan
author_facet Karas, J Andreas
Edgeworth, Jonathan
author_sort Karas, J Andreas
collection PubMed
description The video in this section is a copy of a recorded webinar organized by Shionogi to launch cefiderocol to the UK market in September 2020. Dr Andreas Karas presents the key clinical data for this new antibiotic for MDR Gram-negative infections, followed by reflections from Professor Jonathan Edgeworth on the potential use of the new agent in UK clinical practice. Included in the latter is a case study example of a compassionate use case using cefiderocol. The prescribing information for cefiderocol is available at: https://shionogi-eu-content.com/gb/fetcroja/pi.
format Online
Article
Text
id pubmed-8251257
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-82512572021-07-02 Education: An introduction to the core data for cefiderocol with reflections for a possible role within UK clinical practice Karas, J Andreas Edgeworth, Jonathan JAC Antimicrob Resist Supplement Papers The video in this section is a copy of a recorded webinar organized by Shionogi to launch cefiderocol to the UK market in September 2020. Dr Andreas Karas presents the key clinical data for this new antibiotic for MDR Gram-negative infections, followed by reflections from Professor Jonathan Edgeworth on the potential use of the new agent in UK clinical practice. Included in the latter is a case study example of a compassionate use case using cefiderocol. The prescribing information for cefiderocol is available at: https://shionogi-eu-content.com/gb/fetcroja/pi. Oxford University Press 2021-06-15 /pmc/articles/PMC8251257/ /pubmed/34223150 http://dx.doi.org/10.1093/jacamr/dlab053 Text en © The Author(s) 2021. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) ), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Supplement Papers
Karas, J Andreas
Edgeworth, Jonathan
Education: An introduction to the core data for cefiderocol with reflections for a possible role within UK clinical practice
title Education: An introduction to the core data for cefiderocol with reflections for a possible role within UK clinical practice
title_full Education: An introduction to the core data for cefiderocol with reflections for a possible role within UK clinical practice
title_fullStr Education: An introduction to the core data for cefiderocol with reflections for a possible role within UK clinical practice
title_full_unstemmed Education: An introduction to the core data for cefiderocol with reflections for a possible role within UK clinical practice
title_short Education: An introduction to the core data for cefiderocol with reflections for a possible role within UK clinical practice
title_sort education: an introduction to the core data for cefiderocol with reflections for a possible role within uk clinical practice
topic Supplement Papers
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8251257/
https://www.ncbi.nlm.nih.gov/pubmed/34223150
http://dx.doi.org/10.1093/jacamr/dlab053
work_keys_str_mv AT karasjandreas educationanintroductiontothecoredataforcefiderocolwithreflectionsforapossiblerolewithinukclinicalpractice
AT edgeworthjonathan educationanintroductiontothecoredataforcefiderocolwithreflectionsforapossiblerolewithinukclinicalpractice

Ejemplares similares